Grants and Contributions:
Title:
Pre-clinical R and D of a novel non-opioid drug for the treatment of chronic pain
Agreement Number:
1024974
Agreement Value:
$44,400.00
Agreement Date:
Nov 1, 2024 - Oct 31, 2025
Description:
There is an urgent need to identify new therapeutic approaches for pain. The company has discovered a non-opioid based regulatory mechanism that provides potent pain relief. The company has validated its’ proprietary compounds on this new pain therapy target and the current project will concentrate on the chemical synthesis and biological validation studies to identify and develop back-up compounds as a risk mitigation strategy for the lead compounds currently in development.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Calgary, Alberta, CA T2L 1Y8
Reference Number:
172-2024-2025-Q3-1024974
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
726311673
Recipient Type:
For-profit organization
Recipient's Operating Name:
Zymedyne Therapeutics Inc
Recipient's Legal Name:
Zymedyne Therapeutics Inc
Federal Riding Name:
Calgary Confederation
Federal Riding Number:
48005
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
32541